Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | ADH1A | P07327 | 4/20 | 0.35 |
| ▸ | ADH1C | P00326 | 3/20 | 0.35 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.32 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 2/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24739058 | 0.98 | ADH1A (0.38) | ALDH1A1ADH1AADH1CHRH4HRH3 | |
| SCHEMBL15719057 | 0.93 | ALDH1A1 (0.39) | ALDH1A1ADH1AADH1CPAOXCHRM1 | |
| SCHEMBL3188510 | 0.79 | ALDH1A1 (0.46) | ALDH1A1ADH1ALMNAACHEBCHE | |
| SCHEMBL24693692 | 0.78 | LMNA (0.38) | ALDH1A1ADH1AADH1CLMNAACHE | |
| SCHEMBL27952219 | 0.77 | LSS (0.35) | ADH1AADH1C | |
| SCHEMBL29951969 | 0.76 | PHF8 (0.40) | ALDH1A1 | |
| SCHEMBL7805428 | 0.76 | ALDH1A1 (0.42) | ALDH1A1ADH1AADH1CHRH4HRH3 | |
| SCHEMBL13677592 | 0.75 | BCHE (0.40) | ALDH1A1ADH1ALMNAACHEBCHE | |
| SCHEMBL24739060 | 0.74 | ACHE (0.43) | ALDH1A1ACHE | |
| SCHEMBL19718781 | 0.74 | SMYD3 (0.40) | ALDH1A1ADH1AADH1CLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230144106-A1 | COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY | SYROS PHARMACEUTICALS INC (US) | 2023-05-11 | — | — | US | disclosed |
| US-10787444-B2 | Compounds for the modulation of myc activity | SYROS PHARMACEUTICALS, INC. (US) | 2020-09-29 | — | — | US | disclosed |
| US-20180162851-A1 | COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180162851-A1 | COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY | MYC, MYCBP, MYCBP2 | ALDH1A1 2091/4885ADH1A 2058/4885ADH1C 1766/4885 |
| US-20230144106-A1 | COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY | MYC, MYCBP, MYCBP2 | ALDH1A1 2768/4885ADH1A 2542/4885ADH1C 2205/4885 |
| US-10787444-B2 | Compounds for the modulation of myc activity | MYC, MYCBP, MYCBP2 | ALDH1A1 2091/4885ADH1A 2058/4885ADH1C 1766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.